Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: eye disorder therapeutics - Aerie Pharmaceuticals

Drug Profile

Research programme: eye disorder therapeutics - Aerie Pharmaceuticals

Alternative Names: AR 13154; AR-101; AR-13165; AR-13533; AR-202

Latest Information Update: 29 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University Medical Center
  • Developer Aerie Pharmaceuticals; Ramot at Tel Aviv University
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Janus kinase inhibitors; Norepinephrine plasma membrane transport protein inhibitors; Platelet-derived growth factor beta receptor antagonists; Protein kinase C inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic retinopathy; Dry age-related macular degeneration; Neurological disorders
  • No development reported Glaucoma

Most Recent Events

  • 31 Mar 2019 Aerie Pharmaceuticals files an IND application with the US FDA for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
  • 11 Feb 2019 Aerie Pharmaceuticals plans a phase I/II trial of AR 13503 for Neovascular age-related macular degeneration and Diabetic macular oedema in June 2019 (Intravitreal, Implant) (NCT03835884)
  • 01 Aug 2018 Aerie Pharmaceuticals announces intention to submit IND application to the US FDA for AR 13503 in Wet age-related macular degeneration and Diabetic retinopathy in March 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top